Alamar Biosciences (ALMR) 10% Owner Ltd. Sells $4M of Stock

By TradeTexts Research Desk Oct 21, 2026, 8:01 PM EDT

Alamar Biosciences, Inc. (ALMR) business photo

Key Points

Qiming Corporate GP VI, Ltd. sold 142,004 shares of Alamar Biosciences, Inc. at $27.89 each on October 20, 2026, bringing in roughly $4.0 million.
After the trade, Qiming Corporate GP VI, Ltd. indirectly holds 1,851,350 $ALMR shares, down 7.12% from before the trade.
Major institutions like Sands Capital Alternatives, LLC and Samsara BioCapital, LLC expanded their positions in earlier quarters.
Alamar Biosciences trades recently near $31.45, with analysts holding a consensus buy rating and a mean target of $35.40 ahead of November earnings.

Get Alamar Biosciences text alerts

We text you when insiders, Congress, analysts or big funds move on $ALMR.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Alamar Biosciences, Inc. alert may contain errors. Disclosures

Inside Qiming Corporate GP VI's Alamar Biosciences Trade

Major shareholder Qiming Corporate GP VI, Ltd. sold 142,004 shares of Alamar Biosciences, Inc. (NasdaqGS: ALMR) on October 20, 2026. According to a Form 4 filing with the SEC, the transaction took place at an average price of $27.89 per share, totaling about $4.0 million. Following this transaction, the institutional owner holds 1,851,350 shares, cutting its stake roughly 7.12%. This transaction follows an earlier sale by the same owner on October 15, 2026, when it sold 173,537 shares.

ALMR Alamar Biosciences, Inc.

$28.16 +17.73% past 3 months

Daily close · Oct 20, 2026

Other Institutional Activity in Alamar Biosciences

Other large funds have adjusted their holdings in Alamar Biosciences recently. Sands Capital Alternatives, LLC grew its holdings by 2,115,463 shares, ending with 4,230,926 shares worth about $133.1 million. Samsara BioCapital, LLC added 1,240,155 shares to hold 2,480,310 shares valued at roughly $78.0 million. ARK Investment Management, LLC boosted its stake by 686,980 shares, finishing with 1,373,959 shares valued near $43.2 million. Braidwell LP increased its holdings by 541,992 shares to reach 1,083,983 shares worth about $34.1 million. Alliancebernstein L.P. added 501,538 shares, wrapping up the period with 1,003,077 shares valued at around $31.5 million.

Alamar Biosciences, Inc. Stock Up 11.7%

Alamar Biosciences shares recently traded around $31.45, sitting above its 50-day moving average of $31.01 and its 200-day moving average of $26.63. The stock closed at $28.16 on the transaction date. It is up about 11.7% since that trade.

Recent Earnings

Alamar Biosciences reported trailing twelve month revenue of $100.4 million alongside an EPS of -$1.20. The company's next earnings report is scheduled for November 3, 2026.

Insider Buying and Selling at Alamar Biosciences, Inc.

Insiders have been active in the stock throughout the year. Director Nicholas J. Naclerio bought 235,294 shares on April 20, 2026, for $5.2 million. Illumina Innovation Fund II Gp also picked up 235,294 shares on the same date.

Analysts Set New Price Targets

Wall Street firms remain positive on the proteomics company. Stifel maintained a buy rating on August 11, 2026, lifting its target to $32.00. JP Morgan maintained an overweight rating the same day, raising its target to $35.00.

About Alamar Biosciences

Alamar Biosciences, Inc. operates out of Fremont, California, focusing on proteomics and the early detection of diseases. The company develops the NULISA technology platform, selling specialized instruments, consumables, and services to researchers. This insider sale highlights ongoing portfolio adjustments by major stakeholders as the company prepares for its next earnings release.

Bottom Line

Investors will watch the upcoming November 3 earnings release for updates on revenue growth and product adoption. Further SEC filings will show whether major owners continue trimming their positions.